These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The cost-effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting. Hakimi Z; Wilson K; McAughey E; Pochopien M; Wojciechowski P; Toumi M; Knight C; Sarda SP; Patel N; Wiseman C; de Castro NP; Nazir J; Kelly RJ J Comp Eff Res; 2022 Sep; 11(13):969-985. PubMed ID: 35796199 [No Abstract] [Full Text] [Related]
23. Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress. Peffault de Latour R; Hosokawa K; Risitano AM Semin Hematol; 2022 Jan; 59(1):38-46. PubMed ID: 35491057 [TBL] [Abstract][Full Text] [Related]
24. Role of Complement in Autoimmune Hemolytic Anemia. Berentsen S Transfus Med Hemother; 2015 Sep; 42(5):303-10. PubMed ID: 26696798 [TBL] [Abstract][Full Text] [Related]
25. Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias. Al-Samkari H; van Beers EJ Ther Adv Hematol; 2021; 12():20406207211066070. PubMed ID: 34987744 [TBL] [Abstract][Full Text] [Related]
26. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3. Risitano AM; Perna F; Selleri C Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403 [TBL] [Abstract][Full Text] [Related]
27. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992 [TBL] [Abstract][Full Text] [Related]
28. Pegcetacoplan: First Approval. Hoy SM Drugs; 2021 Aug; 81(12):1423-1430. PubMed ID: 34342834 [TBL] [Abstract][Full Text] [Related]
29. [Current treatment of paroxysmal nocturnal hemoglobinuria and prospects for new therapeutic agents in the future]. Nishimura JI Rinsho Ketsueki; 2021; 62(5):378-387. PubMed ID: 34108318 [TBL] [Abstract][Full Text] [Related]
30. Confounding factors in the diagnosis and clinical course of rare congenital hemolytic anemias. Fattizzo B; Giannotta JA; Cecchi N; Barcellini W Orphanet J Rare Dis; 2021 Oct; 16(1):415. PubMed ID: 34627331 [TBL] [Abstract][Full Text] [Related]
32. Small Paroxysmal Nocturnal Hemoglobinuria Clones in Autoimmune Hemolytic Anemia: Clinical Implications and Different Cytokine Patterns in Positive and Negative Patients. Fattizzo B; Giannotta J; Zaninoni A; Kulasekararaj A; Cro L; Barcellini W Front Immunol; 2020; 11():1006. PubMed ID: 32582157 [TBL] [Abstract][Full Text] [Related]
33. Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Mastellos DC; Ricklin D; Yancopoulou D; Risitano A; Lambris JD Expert Rev Hematol; 2014 Oct; 7(5):583-98. PubMed ID: 25213458 [TBL] [Abstract][Full Text] [Related]
34. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419 [TBL] [Abstract][Full Text] [Related]
35. The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments. Lee JW; Brodsky RA; Nishimura JI; Kulasekararaj AG Expert Rev Clin Pharmacol; 2022 Jul; 15(7):851-861. PubMed ID: 35980222 [TBL] [Abstract][Full Text] [Related]
36. Warm autoimmune hemolytic anemia and the best treatment strategies. Kuter DJ Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):105-113. PubMed ID: 36485114 [TBL] [Abstract][Full Text] [Related]
37. Oxidative stress in paroxysmal nocturnal hemoglobinuria and other conditions of complement-mediated hemolysis. Fibach E; Dana M Free Radic Biol Med; 2015 Nov; 88(Pt A):63-9. PubMed ID: 25937178 [TBL] [Abstract][Full Text] [Related]
38. Safety of current treatments for paroxysmal nocturnal hemoglobinuria. Lee SE; Lee JW Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943 [No Abstract] [Full Text] [Related]
39. [Congenital hemolytic anemias due to erythrocyte membrane and enzyme defects]. Génevaux F; Bertsch A; Wiederer L; Eber S Dtsch Med Wochenschr; 2022 Sep; 147(19):1266-1276. PubMed ID: 36126925 [TBL] [Abstract][Full Text] [Related]
40. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. de Castro C; Grossi F; Weitz IC; Maciejewski J; Sharma V; Roman E; Brodsky RA; Tan L; Di Casoli C; El Mehdi D; Deschatelets P; Francois C Am J Hematol; 2020 Nov; 95(11):1334-1343. PubMed ID: 33464651 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]